SAGE-718
 | |
| IUPAC ime | |
|---|---|
(3S,8R,9S,10R,13R,14S,17R)-3,13-Dimetil-17-[(2R,5S)-6,6,6-trifluoro-5-hidroksi-5-metilheksan-2-il]-2,4,7,8,9,10,11,12,14,15,16,17-dodekahidro-1H-ciklopenta[a]Fenantren-3-ol | |
| Pravni status | |
| Pravni status |
|
| Identifikatori | |
| CAS broj | 2311911-06-3 |
| PubChem | CID 134452289 |
| Hemijski podaci | |
| Formula | C26H41F3O2 |
| Molarna masa | 442,61 g·mol−1 |
SAGE-718 (Nezaštićeni naziv: Dalzanemdor[1]) je eksperimentalni lek koji se istražuje za lečenje neuroloških poremećaja i kognitivnih oštećenja.[2] On deluje kao pozitivan alosterični modulator NMDA receptora, čija je aktivnost neophodna za učenje, pamćenje i kogniciju.[3] SAGE-718 je analog neurosteroida 24S-hidroksiholesterola.[3]
Prema podacima iz 2022. godine, SAGE-718 je u fazi II kliničkih ispitivanja[3] za Alchajmerovu bolest,[4][5][6] Parkinsonovu bolest i Hantingtonovu bolest.[7][8]
Reference[уреди | уреди извор]
- ^ „Investigational SAGE-718 Granted Nonproprietary Name of Dalzanemdor”. Sage Therapeutics. 5. 12. 2023.
- ^ Hill MD, Blanco MJ, Salituro FG, Bai Z, Beckley JT, Ackley MA, et al. (јул 2022). „SAGE-718: A First-in-Class N-Methyl-d-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment”. Journal of Medicinal Chemistry. 65 (13): 9063—9075. doi:10.1021/acs.jmedchem.2c00313.
- ^ а б „SAGE-718”. ALZFORUM.
- ^ Shapiro L (5. 4. 2022). „#AAN2022 – SAGE-718 May Help With Cognitive Function in Alzheimer's”. BioNews, Inc.
- ^ „SAGE-718 in Patients With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease: Results From the Phase 2 LUMINARY Study” (PDF). American Academy of Neurology (AAN) 74th Annual Meeting Abstract.
- ^ Castañeda R (16. 11. 2021). „Regulatory roundup: Sage Alzheimer's asset likely to progress after Phase IIa completion”. Clinical Trials Arena. Архивирано из оригинала 28. 05. 2022. г. Приступљено 20. 12. 2023.
- ^ „Sage Therapeutics Provides Important Update On The Clinical Development Program For Sage's Investigational Drug, SAGE-718.”. Huntington's Disease Society of America. 22. 2. 2022.
- ^ Wexler M (21. 9. 2021). „SAGE-718 on FDA Fast Track as Potential Huntington's Disease Therapy”. BioNews, Inc.
